

2. The transdermal preparation according to claim 1, further comprising at least one additional component chosen from a solubilizer and a skin permeation enhancer.

Sub B4 3. The transdermal preparation according to claim 1, wherein the amount of drug present in the preparation is in a range of 1-50% by weight, based on the total weight of the preparation.

4. The transdermal preparation according to claim 1, wherein the molecular weight of the poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 100-30000, and wherein the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether present in the preparation is in a range of 0.01-50% by weight based on the total weight of the preparation.

5. The transdermal preparation according to claim 4, wherein the molecular weight of the poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 400-5000, and wherein the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether present in the preparation is in a range of 0.05-30 % by weight based on the total weight of the preparation.

6. The transdermal preparation according to claim 1, wherein the drug is selected from a group consisting of sodium, potassium and diethylammonium salts of diclofenac, amfenac, aceclofenac and alclofenac; ketorolac tromethamine; hydrochloride, phosphate and methanesulfonate salts of eperisone and tolperisone; oxybutynin chloride; hydrochloride, hydrobromate, fumarate, succinate and tartrate salts of diphenhydramine, ketotifen, doxylamine, promethazine and trimeprazine; hydrochloride and sulfate salts of tulobuterol, clenbuterol, procaterol and terbutaline; acetate, succinate, valerate and disodium phosphate salts of hydrocortisone, dexamethasone and betamethasone; and hydrochloride salts of ondansetron, granisetron and ramosetron.

Sub B4  
Cont

7. The transdermal preparation according to claim 2, wherein the solubilizer comprises at least one component selected from a group consisting of ethanol, isopropanol, poly(ethylene glycol), ethoxydiglycol, distilled water, propylene glycol, glycerin and dimethylsulfoxide, and wherein the amount of solubilizer present in the preparation is in a range of 0.5-50% by weight based on the total weight of the preparation.

8. The transdermal preparation according to claim 2, wherein the skin permeation enhancer comprises at least one component selected from a group consisting of higher fatty acids; higher alcohols; higher fatty acid esters; fatty acid esters; fatty acid ethers of poly(ethylene glycol); fatty acid esters of poly(ethylene glycol); fatty acid ethers of propylene glycol; fatty acid esters of propylene glycol; sorbitan fatty acid esters; poly(ethylene glycol) sorbitan fatty acid esters; terpenes; sulfoxides; pyrrolidones; amides; and *N*-hydroxy methyl lactate, sorbitol, urea, squalene, olive oil, mineral oil and its derivative, and wherein the amount of skin permeation enhancer present in the preparation is in a range of 0.5-50% by weight based on the total weight of the preparation.

9. The transdermal preparation according to claim 8, wherein the skin permeation enhancer comprises at least one component selected from a group consisting of lauric acid, oleic acid, lauryl alcohol, oleyl alcohol, glycerol monolaurate, glycerol monooleate, polyoxyethylene(2) lauryl ether, polyoxyethylene(2) oleyl ether, propylene glycol monolaurate, propylene glycol monooleate, sorbitan monolaurate, sorbitan monooleate, lauryl diethanolamide, *N*-methyl-2-pyrrolidone and isopropyl myristate.

Sub B5

10. The transdermal preparation according to claim 7, wherein the amount of solubilizer and the amount of skin permeation enhancer present in the preparation are each in a range of 1-30% by weight, based on the total weight of the preparation.

**B.) Please add new claims 11-17.**

Sub B5  
Cont / 11. The transdermal preparation according to claim 2, wherein the amount of drug present in the preparation is in a range of 1-50% by weight, based on the total weight of the preparation.

12. The transdermal preparation according to claim 2, wherein the molecular weight of the poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 100-30000, and the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether present in the preparation is in a range of 0.01-50% by weight based on the total weight of the preparation.

13. The transdermal preparation according to claim 2, wherein the drug is selected from a group consisting of sodium, potassium and diethylammonium salts of diclofenac, amfenac, aceclofenac and alclofenac; ketorolac tromethamine; hydrochloride, phosphate and methanesulfonate salts of eperisone and tolperisone; oxybutynin chloride; hydrochloride, hydrobromate, fumarate, succinate and tartrate salts of diphenhydramine, ketotifen, doxylamine, promethazine and trimeprazine; hydrochloride and sulfate salts of tulobuterol, clenbuterol, procaterol and terbutaline; acetate, succinate, valerate and disodium phosphate salts of hydrocortisone, dexamethasone and betamethasone; and hydrochloride salts of ondansetron, granisetron and ramosetron.

14. The transdermal preparation according to claim 8, wherein the amount of solubilizer and the amount of skin permeation enhancer present in the preparation are each in a range of 1-30% by weight, based on the total weight of the preparation.

15. The transdermal preparation according to claim 9, wherein the amount of solubilizer and the amount of skin permeation enhancer present in the preparation are each in a range of 1-30% by weight, based on the total weight of the preparation.

A3  
16. An adhesive for use in the transdermal delivery of a hydrophilic or salt form drug, the adhesive comprising an acrylic polymer including a poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether side chain.

Sub B6  
17. A pharmaceutical dosage form for the transdermal delivery of a hydrophilic or salt form drug, the dosage form comprising an amount of the drug and an adhesive, the adhesive comprising an acrylic polymer including a poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether side chain.

RECEIVED  
JUN 15 2001  
A version of the claims with markings to show the changes made, is provided below.